Hydroxyurea for Sickle Cell Disease: A Systematic Review for Efficacy and Toxicity in Children

American Academy of Pediatrics (AAP) - Tập 122 Số 6 - Trang 1332-1342 - 2008
John J. Strouse1, Sophie Lanzkron2, Mary Catherine Beach3, Carlton Haywood4, Haeseong Park5,3, Catherine Witkop6, Renée F Wilson3, Eric B Bass3, Jodi B Segal3
1Division of Pediatric Hematology, Department of Pediatrics
2Divisions of Hematology
3General Internal Medicine, Department of Medicine
4Departments of Health Policy and Management
5Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland
6General Preventive Medicine, Bloomberg School of Public Health, Baltimore, Maryland

Tóm tắt

CONTEXT. Hydroxyurea is the only approved medication for the treatment of sickle cell disease in adults; there are no approved drugs for children. OBJECTIVE. Our goal was to synthesize the published literature on the efficacy, effectiveness, and toxicity of hydroxyurea in children with sickle cell disease. METHODS. Medline, Embase, TOXLine, and the Cumulative Index to Nursing and Allied Health Literature through June 2007 were used as data sources. We selected randomized trials, observational studies, and case reports (English language only) that evaluated the efficacy and toxicity of hydroxyurea in children with sickle cell disease. Two reviewers abstracted data sequentially on study design, patient characteristics, and outcomes and assessed study quality independently. RESULTS. We included 26 articles describing 1 randomized, controlled trial, 22 observational studies (11 with overlapping participants), and 3 case reports. Almost all study participants had sickle cell anemia. Fetal hemoglobin levels increased from 5%–10% to 15%–20% on hydroxyurea. Hemoglobin concentration increased modestly (∼1 g/L) but significantly across studies. The rate of hospitalization decreased in the single randomized, controlled trial and 5 observational studies by 56% to 87%, whereas the frequency of pain crisis decreased in 3 of 4 pediatric studies. New and recurrent neurologic events were decreased in 3 observational studies of hydroxyurea compared with historical controls. Common adverse events were reversible mild-to-moderate neutropenia, mild thrombocytopenia, severe anemia, rash or nail changes (10%), and headache (5%). Severe adverse events were rare and not clearly attributable to hydroxyurea. CONCLUSIONS. Hydroxyurea reduces hospitalization and increases total and fetal hemoglobin levels in children with severe sickle cell anemia. There was inadequate evidence to assess the efficacy of hydroxyurea in other groups. The small number of children in long-term studies limits conclusions about late toxicities.

Từ khóa


Tài liệu tham khảo

National Newborn Screening and Genetics Resource Center. National Newborn Screening Information System. Available at: www2.uthscsa.edu/nnsis. Accessed November 7, 2007

Makani J, Williams TN, Marsh K. Sickle cell disease in Africa: burden and research priorities. Ann Trop Med Parasitol. 2007;101(1):3–14

Steiner CA, Miller JL. Sickle cell disease patients in U.S. hospitals, 2004. In: HCUP Statistical Brief. Rockville, MD: Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality; 2006

Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive “switching” agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore). 1996;75(6):300–326

Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21(1):37–47

Benkerrou M, Delarche C, Brahimi L, et al. Hydroxyurea corrects the dysregulated L-selectin expression and increased H2O2 production of polymorphonuclear neutrophils from patients with sickle cell anemia. Blood. 2002;99(7):2297–2303

The management of sickle cell disease. In: Management of Sickle Cell Disease. 4th ed. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute, Division of Blood Diseases and Resources; 2002. NIH publication 02–2117

Segal J, Strouse J, Beach M, et al. Hydroxyurea for the Treatment of Sickle Cell Disease Evidence Report. Washington, DC: Agency for Healthcare Research and Quality; 2008. AHRQ publication 08-E007

Berlin JA. Does blinding of readers affect the results of meta-analyses? University of Pennsylvania meta-analysis blinding study group. Lancet. 1997;350(9072):185–186

World Health Organization Collaborating Center for International Drug Monitoring. Causality assessment of suspected adverse reactions. Available at: www.who-umc.org/DynPage.Aspx?Id=22682. Accessed December 16, 2007

Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials. 1996;17(1):1–12

Horsburgh D. Evaluation of qualitative research. J Clin Nurs. 2003;12(2):307–312

Lincoln TM, Rief W. How much do sample characteristics affect the effect size? An investigation of studies testing the treatment effects for social phobia. J Anxiety Disord. 2004;18(4):515–529

Tobin GA, Begley CM. Methodological rigour within a qualitative framework. J Adv Nurs. 2004;48(4):388–396

Marinopoulos SS, Dorman T, Ratanawongsa N, et al. Effectiveness of continuing medical education. Evid Rep Technol Assess (Full Rep). 2007;(149):1–69

Ratanawongsa N, Thomas PA, Marinopoulos SS, et al. The reported validity and reliability of methods for evaluating continuing medical education: a systematic review. Acad Med. 2008;83(3):274–283

Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490

Agency for Healthcare Research and Quality. Grading the strength of a body of evidence. In: Methods Reference Manual for Comparative Effectiveness Reviews, Version 1.0 [Draft posted October 2007] Rockville, MD. Available at: http://effectivehealthcare.ahrq.gov/repFiles/2007_10DraftMethodsGuide.pdf. Accessed September 19, 2008

Jones J. Determining causation from case reports. In: Strom B, ed. Pharmacoepidemiology. 4th ed. West Sussex, England: John Wiley and Sons; 2005:557–571

Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood. 1996;88(6):1960–1964

Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr. 1996;128(6):820–828

Hankins JS, Helton KJ, McCarville MB, et al. Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatr Blood Cancer. 2008;50(2):293–297

de Montalembert M, Brousse V, Elie C, et al. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes. Haematologica. 2006;91(1):125–128

de Montalembert M, Belloy M, Bernaudin F, et al. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease. J Pediatr Hematol Oncol. 1997;19(4):313–318

Ferster A, Tahriri P, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood. 2001;97(11):3628–3632

Gulbis B, Haberman D, Dufour D, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood. 2005;105(7):2685–2690

Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005;106(7):2269–2275

Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood. 1999;94(5):1550–1554

Maier-Redelsperger M, de Montalembert M, Flahault A, et al. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease. Blood. 1998;91(12):4472–4479

Olivieri NF, Vichinsky EP. Hydroxyurea in children with sickle cell disease: impact on splenic function and compliance with therapy. J Pediatr Hematol Oncol. 1998;20(1):26–31

Santos A, Pinheiro V, Anjos C, et al. Scintigraphic follow-up of the effects of therapy with hydroxyurea on splenic function in patients with sickle cell disease. Eur J Nucl Med Mol Imaging. 2002;29(4):536–541

Svarch E, Machin S, Nieves RM, et al. Hydroxyurea treatment in children with sickle cell anemia in Central America and the Caribbean countries. Pediatr Blood Cancer. 2006;47(1):111–112

Wang WC, Wynn LW, Rogers ZR, et al. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr. 2001;139(6):790–796

Ware RE, Eggleston B, Redding-Lallinger R, et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood. 2002;99(1):10–14

Ware RE, Zimmerman SA, Sylvestre PB, et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr. 2004;145(3):346–352

Harrod VL, Howard TA, Zimmerman SA, Dertinger SD, Ware RE. Quantitative analysis of Howell-Jolly bodies in children with sickle cell disease. Exp Hematol. 2007;35(2):179–183

Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103(6):2039–2045

de Montalembert M, Bégué P, Bernaudin F, Thuret I, Bachir D, Micheau M. Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. French Study Group on Sickle Cell Disease. Arch Dis Child. 1999;81(5):437–439

Hanft VN, Fruchtman SR, Pickens CV, Rosse WF, Howard TA, Ware RE. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood. 2000;95(11):3589–3593

McKie KT, Hanevold CD, Hernandez C, Waller JL, Ortiz L, McKie KM. Prevalence, prevention, and treatment of microalbuminuria and proteinuria in children with sickle cell disease. J Pediatr Hematol Oncol. 2007;29(3):140–144

Kratovil T, Bulas D, Driscoll MC, Speller-Brown B, McCarter R, Minniti CP. Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease. Pediatr Blood Cancer. 2006;47(7):894–900

Zimmerman SA, Schultz WH, Burgett S, Mortier NA, Ware RE. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood. 2007;110(3):1043–1047

Schultz WH, Ware RE. Malignancy in patients with sickle cell disease. Am J Hematol. 2003;74(4):249–253

Scothorn DJ, Price C, Schwartz D, et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr. 2002;140(3):348–354

Wilimas J, Goff JR, Anderson HR Jr, Langston JW, Thompson E. Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents. J Pediatr. 1980;96(2):205–208

Thompson J, Reid M, Hambleton I, Serjeant GR. Albuminuria and renal function in homozygous sickle cell disease: observations from a cohort study. Arch Intern Med. 2007;167(7):701–708

Liebelt EL, Balk SJ, Faber W, et al. NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea. Birth Defects Res B Dev Reprod Toxicol. 2007;80(4):259–366

Shelby MD; Center for the Evaluation of Risks to Human Reproduction Expert Panel. National Toxicology Program Center for the Evaluation of Risks to Human Reproduction: guidelines for CERHR expert panel members. Birth Defects Res B Dev Reprod Toxicol. 2005;74(1):9–16

Al-Jam'a AH, Al-Dabbous IA, Al-Khatti AA, Esan FG. Are we underestimating the leukemogenic risk of hydroxyurea. Saudi Med J. 2002;23(11):1411–1413

Wilson S. Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea. Ann Intern Med. 2000;133(11):925–926

Rauch A, Borremeo M, Ghafoor A, Khoyratty B, Maheshwari J. Leukemogenesis of hydroxyurea in the treatment of sickle cell anemia [abstract]. Blood. 1999;94(suppl 1):415a

Kattamis A, Lagona E, Orfanou I, et al. Clinical response and adverse events in young patients with sickle cell disease treated with hydroxyurea. Pediatr Hematol Oncol. 2004;21(4):335–342

Moschovi M, Psychou F, Menegas D, et al. Hodgkin's disease in a child with sickle cell disease treated with hydroxyurea. Pediatr Hematol Oncol. 2001;18(6):371–376

O'Branski EE, Ware RE, Prose NS, Kinney TR. Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy. J Am Acad Dermatol. 2001;44(5):859–861

Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332(20):1317–1322

Grigg A. Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease. Intern Med J. 2007;37(3):190–192

Lorey FW, Arnopp J, Cunningham GC. Distribution of hemoglobinopathy variants by ethnicity in a multiethnic state. Genet Epidemiol. 1996;13(5):501–512

Thông tin
Thông tin xuất bản

American Academy of Pediatrics (AAP)

Tập 122 Số 6

1332-1342

Thông tin tác giả